UroGen Pharma Ltd.(URGN)

Description: UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.

---

Keywords: Medicine Cancer Biopharmaceutical Surgery Immunotherapy Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Overactive Bladder Botulinum Toxin Oab Tlr7 Two Platform Technologies Urinary Bladder Interstitial Cystitis Non Muscle Invasive Bladder Cancer Urothelial Cancer

---

Home Page: www.urogen.com

URGN Technical Analysis

400 Alexander Park
Princeton, NJ 08540
United States
Phone: 646 768 9780

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)